Filing search / Kineta, Inc. / "Strategy"

8-K

EX-99.1

KANT Kineta, Inc.

8 Oct 24

Kineta Announces Completion of Enrollment in the Monotherapy Arm of the VISTA-101 Phase 1 Clinical Study in Advanced Solid Tumors

9:05am

commercialization, marketing and manufacturing capabilities and strategy; developments and projections relating to Kineta’s competitors and its industry

8-K

EX-99.1

KANT Kineta, Inc.

4 Oct 24

Kineta Announces KVA12123 Abstract Accepted for Poster Presentation at Society for Immunotherapy of Cancer (SITC) 2024

9:05am

acceptance of Kineta’s product candidates; Kineta’s commercialization, marketing and manufacturing capabilities and strategy; developments and projections

8-K

EX-99.1

KANT Kineta, Inc.

2 Oct 24

Kineta and TuHURA are collaborating on the ongoing Phase 1/Phase 2 clinical trial in patients with advance solid tumor cancer

4:07pm

of Kineta’s product candidates; Kineta’s commercialization, marketing and manufacturing capabilities and strategy; developments and projections relating

8-K

EX-99.1

KANT Kineta, Inc.

19 Sep 24

Other Events

9:53pm

product candidates; Kineta’s commercialization, marketing and manufacturing capabilities and strategy; developments and projections relating to Kineta’s

8-K

EX-99.1

KANT Kineta, Inc.

19 Aug 24

Kineta Reopens Enrollment for the VISTA-101 Clinical Trial Evaluating KVA12123 in Patients with Advanced Solid Tumor Cancer

9:01am

and manufacturing capabilities and strategy; developments and projections relating to Kineta’s competitors and its industry; the impact of government laws

8-K

EX-99.1

8zaqfgbhkw

8 Jul 24

Kineta Announces Exclusivity and Right of First Offer Agreement for its VISTA blocking antibody with TuHURA Biosciences

6:30am

8-K

EX-99.1

nmu8oc5 0a4h0

15 May 24

Kineta Reports First Quarter 2024 Financial Results and Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial and Corporate Activities

4:03pm

8-K

EX-99.1

w7405oj

8 Apr 24

Kineta Reports Initial Clinical Response Data at AACR 2024 of its Ongoing Phase 1/2 VISTA-101 Clinical Trial

4:02pm

8-K

EX-99.1

steprtlpt

21 Mar 24

Kineta Reports Full Year 2023 Financial Results and Provides Corporate Update

4:04pm

8-K

a43lp49

12 Mar 24

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

8:05am

8-K

EX-99.2

eqj9gtc aym57qptn

12 Mar 24

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

8:05am

8-K

EX-99.1

xge9marmktvsgdq8

12 Mar 24

Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts

8:05am

8-K

EX-99.1

g1r c4fl7rjzfq9gf

17 Jan 24

Kineta Provides Update on its Ongoing Phase 1/2 VISTA-101 Clinical Trial of KVA12123 in Patients with Advanced Solid Tumors

8:30am

8-K

EX-99.1

ipgdwl8

5 Jan 24

Regulation FD Disclosure

4:30pm

424B3

bp940lzyb7bb5hfw7m9

13 Nov 23

Prospectus supplement

5:28pm

8-K

EX-99.2

qf4i 9bh77d

6 Nov 23

Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

8:30am